These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3020821)

  • 21. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
    J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
    Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
    Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.
    Bystrická M; Petríková M; Zatovicová M; Soláriková L; Kostolanský F; Mucha V; Russ G
    Acta Virol; 1997 Feb; 41(1):5-12. PubMed ID: 9199708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical characterization of herpes simplex virus type-1-immunostimulating complexes (ISCMOs): a multi-glycoprotein structure.
    Erturk M; Jennings R; Phillpotts RJ; Potter CW
    Vaccine; 1991 Sep; 9(9):668-74. PubMed ID: 1659055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of glycosylation of herpes simplex virus glycoproteins: identification of antigenic and immunogenic partially glycosylated glycopeptides on the cell surface membrane.
    Glorioso J; Szczesiul MS; Marlin SD; Levine M
    Virology; 1983 Apr; 126(1):1-18. PubMed ID: 6189286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of the B lymphocyte precursor frequencies to herpes simplex type 1 glycoproteins by a limiting dilution assay.
    Turtinen LW; Lathey JL; Rouse BT
    J Med Virol; 1986 Dec; 20(4):357-62. PubMed ID: 3025354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems.
    Hassan Y; Brewer JM; Alexander J; Jennings R
    Vaccine; 1996 Dec; 14(17-18):1581-9. PubMed ID: 9032885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
    Geerligs HJ; Kocken CH; Drijfhout JW; Weijer WJ; Bloemhoff W; Wilterdink JB; Welling GW; Welling-Wester S
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
    Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
    J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel strategy for converting recombinant viral protein into high immunogenic antigen.
    Hinuma S; Hazama M; Mayumi A; Fujisawa Y
    FEBS Lett; 1991 Aug; 288(1-2):138-42. PubMed ID: 1652468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
    Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
    Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
    Martin S; Mercadal CM; Weir JP; Rouse BT
    Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies against herpes simplex viruses.
    Scheffer AJ; Koedijk DG; Abee T; Osterhaus AD
    Dev Biol Stand; 1984; 57():269-74. PubMed ID: 6098497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different mechanisms of protection by monoclonal and polyclonal antibodies during the course of herpes simplex virus infection.
    Eis-Hübinger AM; Mohr K; Schneweis KE
    Intervirology; 1991; 32(6):351-60. PubMed ID: 1657825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
    Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
    Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
    Chan WL; Lukig ML; Liew FY
    J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody reactivity with Skinner HSV vaccine.
    Muniu EM; Durham J; Shariff D; Hartley CE; Fuller A; Melling J; Wiblin C; Wilkins G; Buchan A; Skinner GR
    Med Microbiol Immunol; 1987; 176(6):315-27. PubMed ID: 2828898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.